Recent Updates
Recently added Catalysts

BMS-986548

Phase 1/2

Advanced Solid Malignancies | Small Molecules | Oncology |Bristol-Myers Squibb Company|Trials Updated: Nov 16, 2026

BMS-986548 development status

Highest phase Phase 1/2
Registered trials 1 across 1 sponsor since Nov 2026

Success Probability

Subscribe to view

Market & Valuation

Subscribe to view

Trial Design

CONTROLLEDBiomarker
Total Trials1
Total Enrollment171

FDA Designations

No designations recorded

BMS-986548 clinical trials

BMS-986548 · 1 trial · 1 indication

Phase 1/2 1
NCT07939815A Study of BMS-986548 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid MalignanciesAdvanced Solid Malignancies
NOT YET_RECRUITING171 Analytics
PHASE1/PHASE2NOT YET_RECRUITING
A Study of BMS-986548 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Malignancies
Advanced Solid MalignanciesUnlock trial analytics

Study Endpoints

Primary Endpoints

Number of participants with adverse events (AEs)
Up to 30 days after last dose
Number of participants with serious adverse events (SAEs)
Up to 30 days after last dose
Number of participants with AEs meeting protocol defined Dose-Limiting Toxicity (DLT) criteria
Up to 30 days after last dose
Number of participants with AEs leading to discontinuation
Up to 30 days after last dose
Number of deaths
Up to 30 days after last dose

Secondary Endpoints

Objective Response Rate (ORR) per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1
Up to 3 years
Duration of Response (DOR) per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1
Up to 3 years
Maximum observed concentration (Cmax)
Up to 3 years
Unlock Study Endpoints

Study Design & Arms

AllocationNON_RANDOMIZED
MaskingNONE
ModelSEQUENTIAL
PurposeTREATMENT

Treatment Arms

ArmTypeDescription
Part 1A Monotherapy Dose Escalation: BMS-986548EXPERIMENTAL -
Part 1B Combination Dose Escalation: BMS-986548 + CetuximabEXPERIMENTAL -
Part 2A Monotherapy Dose Expansion: BMS-986548EXPERIMENTAL -
Part 2B Combination Dose Expansion: BMS-986548 + CetuximabEXPERIMENTAL -

Interventions

NameTypeDescription
BMS-986548DRUGSpecified dose on specified days
CetuximabDRUGSpecified dose on specified days
Unlock Study Design Details

Eligibility Criteria

Age Range18 Years to N/A
SexALL
Healthy VolunteersNo
Study Sites4

Inclusion Criteria * Participants must have a histologically confirmed diagnosis of a locally advanced and unresectable or metastatic solid tumor malignancy with a known Kirsten rat sarcoma viral oncogene homolog (KRAS) alteration (mutation or amplification). * Participants must have an Eastern Coo...

Countries:United StatesCanada
Unlock Eligibility Criteria

Recent Changes (Last 90 Days)

LOWNov 16, 2026NCT07939815New Trial Detected: Not Yet Recruiting

Frequently asked questions about BMS-986548

What is BMS-986548 used for?

BMS-986548 is an investigational small molecule being studied for the treatment of advanced solid malignancies. It is being evaluated both as a monotherapy and in combination with anti-cancer agents in adults with these advanced cancers. It is not yet an approved treatment.

Who is developing BMS-986548?

BMS-986548 is being developed by Bristol-Myers Squibb Company, which trades under the ticker BMY. The company is the sponsor of the clinical program evaluating the compound in advanced solid malignancies.

What phase is BMS-986548 in?

BMS-986548 is in Phase 1/2 clinical development. It is investigational and has not been approved by the FDA. The program consists of a single Phase 1/Phase 2 study that is currently active but not yet recruiting participants.

What clinical trial is BMS-986548 being studied in?

BMS-986548 is being studied in trial NCT07939815, titled a study of BMS-986548 as monotherapy and in combination with anti-cancer agents in participants with advanced solid malignancies. The Phase 1/Phase 2 trial is not yet recruiting and plans to enroll 171 participants across the United States and Canada.

Who can enroll in the BMS-986548 trial?

The NCT07939815 trial enrolls adults aged 18 years and older of all sexes with advanced solid malignancies. It does not include healthy volunteers, and the study is biomarker selected, meaning participants are chosen based on a defined biomarker. The trial is controlled and is not randomized or double blinded.